Intrinsic value of Intellia Therapeutics - NTLA

Previous Close

$17.32

  Intrinsic Value

$2.58

stock screener

  Rating & Target

str. sell

-85%

Previous close

$17.32

 
Intrinsic value

$2.58

 
Up/down potential

-85%

 
Rating

str. sell

We calculate the intrinsic value of NTLA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  29.70
  27.23
  25.01
  23.01
  21.21
  19.59
  18.13
  16.81
  15.63
  14.57
  13.61
  12.75
  11.98
  11.28
  10.65
  10.09
  9.58
  9.12
  8.71
  8.34
  8.00
  7.70
  7.43
  7.19
  6.97
  6.77
  6.60
  6.44
  6.29
  6.16
Revenue, $m
  34
  43
  54
  66
  80
  96
  113
  133
  153
  176
  199
  225
  252
  280
  310
  341
  374
  408
  444
  481
  519
  559
  601
  644
  689
  736
  784
  835
  887
  942
Variable operating expenses, $m
  100
  128
  160
  196
  238
  285
  336
  393
  454
  520
  591
  666
  746
  830
  919
  1,011
  1,108
  1,209
  1,314
  1,424
  1,538
  1,656
  1,780
  1,907
  2,040
  2,179
  2,322
  2,472
  2,627
  2,789
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  100
  128
  160
  196
  238
  285
  336
  393
  454
  520
  591
  666
  746
  830
  919
  1,011
  1,108
  1,209
  1,314
  1,424
  1,538
  1,656
  1,780
  1,907
  2,040
  2,179
  2,322
  2,472
  2,627
  2,789
Operating income, $m
  -66
  -85
  -106
  -130
  -158
  -188
  -223
  -260
  -301
  -345
  -391
  -441
  -494
  -550
  -608
  -670
  -734
  -801
  -871
  -943
  -1,019
  -1,097
  -1,179
  -1,263
  -1,352
  -1,443
  -1,538
  -1,637
  -1,740
  -1,848
EBITDA, $m
  -63
  -80
  -100
  -123
  -150
  -179
  -211
  -247
  -285
  -327
  -372
  -419
  -469
  -522
  -578
  -636
  -697
  -760
  -826
  -895
  -967
  -1,042
  -1,119
  -1,199
  -1,283
  -1,370
  -1,460
  -1,554
  -1,652
  -1,754
Interest expense (income), $m
  0
  0
  0
  1
  3
  4
  6
  8
  10
  12
  15
  18
  21
  24
  27
  31
  35
  39
  43
  47
  51
  56
  61
  66
  71
  76
  82
  88
  94
  100
  107
Earnings before tax, $m
  -66
  -85
  -107
  -133
  -162
  -194
  -231
  -270
  -313
  -360
  -409
  -462
  -518
  -577
  -639
  -705
  -773
  -844
  -918
  -995
  -1,075
  -1,158
  -1,245
  -1,334
  -1,428
  -1,525
  -1,626
  -1,731
  -1,841
  -1,954
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -66
  -85
  -107
  -133
  -162
  -194
  -231
  -270
  -313
  -360
  -409
  -462
  -518
  -577
  -639
  -705
  -773
  -844
  -918
  -995
  -1,075
  -1,158
  -1,245
  -1,334
  -1,428
  -1,525
  -1,626
  -1,731
  -1,841
  -1,954

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  87
  111
  138
  170
  206
  247
  292
  341
  394
  451
  513
  578
  647
  721
  797
  878
  962
  1,049
  1,141
  1,236
  1,335
  1,438
  1,544
  1,655
  1,771
  1,891
  2,016
  2,145
  2,280
  2,421
Adjusted assets (=assets-cash), $m
  87
  111
  138
  170
  206
  247
  292
  341
  394
  451
  513
  578
  647
  721
  797
  878
  962
  1,049
  1,141
  1,236
  1,335
  1,438
  1,544
  1,655
  1,771
  1,891
  2,016
  2,145
  2,280
  2,421
Revenue / Adjusted assets
  0.391
  0.387
  0.391
  0.388
  0.388
  0.389
  0.387
  0.390
  0.388
  0.390
  0.388
  0.389
  0.389
  0.388
  0.389
  0.388
  0.389
  0.389
  0.389
  0.389
  0.389
  0.389
  0.389
  0.389
  0.389
  0.389
  0.389
  0.389
  0.389
  0.389
Average production assets, $m
  17
  21
  27
  33
  40
  48
  57
  66
  76
  87
  99
  112
  125
  140
  154
  170
  186
  203
  221
  239
  259
  278
  299
  321
  343
  366
  390
  416
  442
  469
Working capital, $m
  -22
  -29
  -36
  -44
  -53
  -64
  -75
  -88
  -101
  -116
  -132
  -149
  -167
  -186
  -205
  -226
  -248
  -270
  -294
  -318
  -344
  -370
  -398
  -426
  -456
  -487
  -519
  -552
  -587
  -623
Total debt, $m
  3
  24
  49
  78
  110
  147
  187
  231
  279
  331
  386
  445
  507
  573
  642
  714
  790
  869
  951
  1,037
  1,126
  1,218
  1,314
  1,414
  1,518
  1,626
  1,738
  1,855
  1,977
  2,103
Total liabilities, $m
  78
  100
  125
  153
  186
  222
  263
  307
  355
  406
  462
  520
  583
  648
  718
  790
  866
  944
  1,027
  1,112
  1,201
  1,294
  1,390
  1,490
  1,594
  1,702
  1,814
  1,931
  2,052
  2,179
Total equity, $m
  9
  11
  14
  17
  21
  25
  29
  34
  39
  45
  51
  58
  65
  72
  80
  88
  96
  105
  114
  124
  133
  144
  154
  166
  177
  189
  202
  215
  228
  242
Total liabilities and equity, $m
  87
  111
  139
  170
  207
  247
  292
  341
  394
  451
  513
  578
  648
  720
  798
  878
  962
  1,049
  1,141
  1,236
  1,334
  1,438
  1,544
  1,656
  1,771
  1,891
  2,016
  2,146
  2,280
  2,421
Debt-to-equity ratio
  0.310
  2.170
  3.540
  4.560
  5.340
  5.940
  6.410
  6.780
  7.080
  7.320
  7.530
  7.690
  7.830
  7.950
  8.050
  8.140
  8.210
  8.280
  8.340
  8.390
  8.430
  8.470
  8.510
  8.540
  8.570
  8.600
  8.620
  8.650
  8.670
  8.690
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -66
  -85
  -107
  -133
  -162
  -194
  -231
  -270
  -313
  -360
  -409
  -462
  -518
  -577
  -639
  -705
  -773
  -844
  -918
  -995
  -1,075
  -1,158
  -1,245
  -1,334
  -1,428
  -1,525
  -1,626
  -1,731
  -1,841
  -1,954
Depreciation, amort., depletion, $m
  3
  4
  5
  7
  8
  10
  11
  13
  15
  17
  20
  22
  25
  28
  31
  34
  37
  41
  44
  48
  52
  56
  60
  64
  69
  73
  78
  83
  88
  94
Funds from operations, $m
  -63
  -80
  -102
  -126
  -154
  -185
  -219
  -257
  -298
  -342
  -389
  -440
  -493
  -549
  -609
  -670
  -735
  -803
  -873
  -947
  -1,023
  -1,102
  -1,185
  -1,270
  -1,359
  -1,452
  -1,548
  -1,648
  -1,752
  -1,861
Change in working capital, $m
  -5
  -6
  -7
  -8
  -9
  -10
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -24
  -25
  -26
  -28
  -29
  -30
  -31
  -32
  -33
  -35
  -36
Cash from operations, $m
  -58
  -74
  -95
  -118
  -144
  -174
  -208
  -244
  -284
  -327
  -374
  -423
  -475
  -531
  -589
  -650
  -714
  -780
  -850
  -922
  -998
  -1,076
  -1,157
  -1,242
  -1,330
  -1,421
  -1,516
  -1,615
  -1,717
  -1,824
Maintenance CAPEX, $m
  -3
  -3
  -4
  -5
  -7
  -8
  -10
  -11
  -13
  -15
  -17
  -20
  -22
  -25
  -28
  -31
  -34
  -37
  -41
  -44
  -48
  -52
  -56
  -60
  -64
  -69
  -73
  -78
  -83
  -88
New CAPEX, $m
  -4
  -5
  -5
  -6
  -7
  -8
  -9
  -10
  -10
  -11
  -12
  -13
  -13
  -14
  -15
  -16
  -16
  -17
  -18
  -18
  -19
  -20
  -21
  -22
  -22
  -23
  -24
  -25
  -26
  -27
Cash from investing activities, $m
  -7
  -8
  -9
  -11
  -14
  -16
  -19
  -21
  -23
  -26
  -29
  -33
  -35
  -39
  -43
  -47
  -50
  -54
  -59
  -62
  -67
  -72
  -77
  -82
  -86
  -92
  -97
  -103
  -109
  -115
Free cash flow, $m
  -64
  -82
  -104
  -129
  -158
  -190
  -226
  -265
  -308
  -354
  -403
  -455
  -511
  -570
  -632
  -696
  -764
  -835
  -908
  -985
  -1,065
  -1,147
  -1,234
  -1,323
  -1,416
  -1,513
  -1,613
  -1,718
  -1,827
  -1,940
Issuance/(repayment) of debt, $m
  3
  21
  25
  29
  33
  36
  40
  44
  48
  52
  55
  59
  62
  66
  69
  72
  76
  79
  82
  86
  89
  93
  96
  100
  104
  108
  112
  117
  121
  126
Issuance/(repurchase) of shares, $m
  84
  87
  110
  136
  165
  198
  235
  275
  319
  365
  415
  469
  525
  585
  647
  713
  781
  852
  927
  1,004
  1,085
  1,168
  1,255
  1,346
  1,439
  1,537
  1,639
  1,744
  1,854
  1,968
Cash from financing (excl. dividends), $m  
  87
  108
  135
  165
  198
  234
  275
  319
  367
  417
  470
  528
  587
  651
  716
  785
  857
  931
  1,009
  1,090
  1,174
  1,261
  1,351
  1,446
  1,543
  1,645
  1,751
  1,861
  1,975
  2,094
Total cash flow (excl. dividends), $m
  22
  26
  31
  35
  40
  45
  49
  54
  59
  63
  68
  72
  76
  81
  85
  89
  93
  97
  101
  105
  109
  113
  118
  122
  127
  132
  138
  143
  149
  155
Retained Cash Flow (-), $m
  -84
  -87
  -110
  -136
  -165
  -198
  -235
  -275
  -319
  -365
  -415
  -469
  -525
  -585
  -647
  -713
  -781
  -852
  -927
  -1,004
  -1,085
  -1,168
  -1,255
  -1,346
  -1,439
  -1,537
  -1,639
  -1,744
  -1,854
  -1,968
Prev. year cash balance distribution, $m
  309
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  248
  -61
  -79
  -101
  -126
  -154
  -186
  -221
  -260
  -302
  -348
  -397
  -449
  -504
  -562
  -624
  -688
  -756
  -826
  -899
  -976
  -1,055
  -1,137
  -1,223
  -1,312
  -1,405
  -1,501
  -1,601
  -1,705
  -1,813
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  237
  -56
  -69
  -83
  -97
  -112
  -125
  -138
  -149
  -158
  -165
  -169
  -171
  -169
  -165
  -159
  -150
  -139
  -127
  -114
  -101
  -88
  -75
  -62
  -51
  -41
  -32
  -25
  -19
  -14
Current shareholders' claim on cash, %
  50.0
  9.9
  2.0
  0.4
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

FINANCIAL RATIOS  of  Intellia Therapeutics (NTLA)

Valuation Ratios
P/E Ratio -19.5
Price to Sales 39
Price to Book 3
Price to Tangible Book
Price to Cash Flow 17.3
Price to Free Cash Flow 20.8
Growth Rates
Sales Growth Rate 166.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 100%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -16.8%
Ret/ On Assets - 3 Yr. Avg. -74.8%
Return On Total Capital -23.1%
Ret/ On T. Cap. - 3 Yr. Avg. -101.7%
Return On Equity -23.1%
Return On Equity - 3 Yr. Avg. -101.7%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -193.8%
EBITDA Margin - 3 Yr. Avg. -136.8%
Operating Margin -206.3%
Oper. Margin - 3 Yr. Avg. -141%
Pre-Tax Margin -200%
Pre-Tax Margin - 3 Yr. Avg. -138.9%
Net Profit Margin -200%
Net Profit Margin - 3 Yr. Avg. -133.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 2.6%
Payout Ratio 0%

NTLA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NTLA stock intrinsic value calculation we used $26.117 million for the last fiscal year's total revenue generated by Intellia Therapeutics. The default revenue input number comes from 0001 income statement of Intellia Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NTLA stock valuation model: a) initial revenue growth rate of 29.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for NTLA is calculated based on our internal credit rating of Intellia Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Intellia Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NTLA stock the variable cost ratio is equal to 296.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for NTLA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Intellia Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Intellia Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NTLA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NTLA are equal to 49.8%.

Life of production assets of 4.3 years is the average useful life of capital assets used in Intellia Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NTLA is equal to -66.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $300.597 million for Intellia Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 43.09 million for Intellia Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Intellia Therapeutics at the current share price and the inputted number of shares is $0.7 billion.

RELATED COMPANIES Price Int.Val. Rating
REGN Regeneron Phar 341.65 335.37  hold
EDIT Editas Medicin 28.08 1.10  str.sell
BLUE bluebird bio 122.78 7.95  str.sell
SGMO Sangamo Therap 10.36 3.03  str.sell
CLLS Cellectis ADR 22.51 2.72  str.sell
FATE Fate Therapeut 12.59 0.37  str.sell

COMPANY NEWS

▶ Cambridge's Editas asks FDA to start gene editing trial   [Nov-07-18 07:46PM  American City Business Journals]
▶ Cambridge's Intellia delays gene editing trial   [Oct-31-18 11:51AM  American City Business Journals]
▶ Here's Why CRISPR Stocks Rose as Much as 18.7% in August   [Sep-04-18 11:29AM  Motley Fool]
▶ Gene Editing is a Major Technology to Watch   [Aug-27-18 01:12PM  InvestorPlace]
▶ Here's Why CRISPR Stocks Are Down as Much as 11.4% Today   [Jul-24-18 04:06PM  Motley Fool]
▶ Yet Another CRISPR Worry: What Should Investors Do?   [Jul-17-18 03:01PM  Motley Fool]
▶ [$$] New Research Prompts Selloff in Companies Using Crispr Technology   [Jul-16-18 07:31PM  The Wall Street Journal]
▶ Biotech Stocks Crispr, Editas, Intellia Fall On Gene-Editing Study   [Jun-11-18 04:20PM  Investor's Business Daily]
▶ What Makes This CRISPR Stock Better Than the Rest?   [May-30-18 03:37PM  Motley Fool]
▶ CRISPR Stocks Deserve a Second Look. Here's Why.   [May-16-18 07:00AM  Investopedia]
▶ Top Gene-Editing Stocks for Long-Term Investors   [May-01-18 04:56PM  Motley Fool]
▶ Big Week in Tech for Amazon, Alphabet and Microsoft   [Apr-20-18 05:12PM  Yahoo Finance Video]
▶ Oops! CRISPR Concerns Turn Out to be a Big Nothingburger   [Apr-03-18 09:32AM  Motley Fool]
▶ 3 Reasons CRISPR Stocks Could Keep Soaring   [Mar-16-18 06:13AM  Motley Fool]
▶ Can CRISPR And These 3 Small Biotechs Cure 10,000 Diseases?   [Feb-02-18 03:10PM  Investor's Business Daily]
▶ Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless   [Jan-08-18 08:00AM  Motley Fool]
▶ Intellia Therapeutics Is Worth Trading Right Now   [Sep-08-17 11:01AM  TheStreet.com]
▶ 3 Stocks That Could Make You Rich   [Aug-15-17 07:54AM  Motley Fool]
▶ Former GSK exec resigns from Intellia board due to 'conflict'   [Aug-10-17 01:39PM  American City Business Journals]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.